Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes
- 1 January 2015
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 746, 50-55
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- 11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular DiseaseDrugs, 2013
- Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY studyPediatric Diabetes, 2012
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Pioglitazone for Diabetes Prevention in Impaired Glucose ToleranceNew England Journal of Medicine, 2011
- Effects of an 11 β ‐hydroxysteroid dehydrogenase type 1 inhibitor, MK‐0916, in patients with type 2 diabetes mellitus and metabolic syndromeDiabetes, Obesity and Metabolism, 2011
- Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2011
- Effect of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dogAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Type 2 diabetes and metabolic syndrome are associated with increased expression of 11β-hydroxysteroid dehydrogenase 1 in obese subjectsInternational Journal of Obesity, 2007
- 11β‐Hydroxysteroid Dehydrogenase Type 1 mRNA is Increased in Both Visceral and Subcutaneous Adipose Tissue of Obese PatientsObesity, 2006
- 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in miceJournal of Experimental Medicine, 2005